| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT01495169 | Safety and Tolerability of Iloperidone | Drug: iloperidone (oral tablet) | Vanda Pharmaceuticals | Phase 1 | 2011-10-01 | 2016-06-10 |
| NCT01207414 | Schizophrenia | Drug: iloperidone | Novartis | Phase 4 | 2010-08-01 | 2013-02-04 |
| NCT02413918 | Bipolar Disorder | Drug: iloperidone | The University of Texas Health Science Center at San Antonio|Novartis Pharmaceuticals | Phase 4 | 2012-04-01 | 2015-04-09 |
| NCT01529294 | Hepatic Impairment | Drug: Iloperidone | Novartis Pharmaceuticals|Novartis | Phase 1 | 2010-08-01 | 2013-03-13 |
| NCT01917318 | Post Traumatic Stress Disorder | Drug: Iloperidone|Drug: Placebo | University of Colorado, Denver|Novartis Pharmaceuticals | Phase 2 | 2013-07-01 | 2014-09-24 |
| NCT01929889 | Schizophrenia|Schizoaffective Disorder | Drug: Iloperidone | Northwestern University|Novartis Pharmaceuticals | Phase 4 | 2012-04-01 | 2015-07-06 |
| NCT01623713 | Schizophrenia|Iloperidone|Efficacy | Drug: iloperidone|Drug: Risperidone | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 2 | 2012-06-01 | 2013-11-17 |
| NCT01348100 | Schizophrenia | Drug: Iloperidone crystalline formulation|Drug: Iloperidone microparticle formulation|Drug: Oral iloperidone | Novartis Pharmaceuticals|Vanda Pharmaceuticals|Novartis | Phase 1|Phase 2 | 2011-04-01 | 2013-12-17 |
| NCT01291511 | Schizophrenia | Drug: Iloperidone|Drug: Placebo | Vanda Pharmaceuticals | Phase 3 | 2011-02-01 | 2016-06-10 |
| NCT01464229 | Major Depressive Disorder | Drug: Iloperidone|Drug: Placebo | Maurizio Fava, MD|Novartis Pharmaceuticals|Massachusetts General Hospital | Phase 4 | 2012-04-01 | 2015-04-14 |
| NCT01920802 | Healthy | Drug: olanzapine|Drug: iloperidone|Drug: Placebo | New York State Psychiatric Institute|Novartis Pharmaceuticals | Phase 4 | 2012-11-01 | 2017-01-30 |
| NCT02453893 | Schizophrenia | Drug: Iloperidone|Drug: Risperidone | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 3 | 2013-11-01 | 2015-05-26 |
| NCT01686815 | Schizophrenia|Serious Mental Illness|Metabolic Syndrome|Insulin Resistance|Glucose Metabolism | David C. Henderson|Novartis Pharmaceuticals|Massachusetts General Hospital | | 2012-10-01 | 2015-04-15 |
| NCT00254202 | Schizophrenia | Drug: iloperidone|Drug: active comparator|Drug: placebo | Vanda Pharmaceuticals | Phase 3 | 2005-11-01 | 2012-07-18 |
| NCT00806234 | Psychotic Disorders | Drug: Aripiprazole or Perphenazine|Drug: Metformin|Drug: Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine | Johns Hopkins University|National Institute of Mental Health (NIMH)|University of Maryland|University of North Carolina, Chapel Hill|The Zucker Hillside Hospital | Phase 4 | 2009-01-01 | 2014-05-15 |
| NCT01498770 | Bipolar Disorder | Drug: Asenapine|Drug: Aripiprazole|Drug: Quetiapine|Drug: Risperidone|Drug: Olanzapine|Drug: Ziprasidone|Drug: Iloperidone|Drug: Paliperidone|Drug: Lurasidone|Drug: Clozapine|Drug: Amisulpride|Drug: Sertindole|Drug: Zotepine | Merck Sharp & Dohme Corp. | | 2013-04-01 | 2017-03-06 |
| NCT02181803 | Schizophrenia | Drug: MK-8189|Drug: Placebo|Drug: Base Monotherapy | Merck Sharp & Dohme Corp. | Phase 1 | 2014-08-01 | 2015-05-05 |
| NCT02600741 | Schizophrenia | Other: Caregiver psycho-education and skills training|Other: Caregiver support available at the study site|Drug: Paliperidone palmitate|Drug: Chlorpromazine|Drug: Droperidol|Drug: Fluphenazine|Drug: Haloperidol|Drug: Loxapine|Drug: Perphenazine|Drug: Pimozide|Drug: Prochlorperazine|Drug: Thiothixene|Drug: Thioridazine|Drug: Trifluoperazine|Drug: Aripiprazole|Drug: Asenapine|Drug: Clozapine|Drug: Iloperidone|Drug: Olanzapine|Drug: Paliperidone|Drug: Quetiapine|Drug: Risperidone|Drug: Ziprasidone | Janssen Scientific Affairs, LLC | | 2015-07-24 | 2017-03-17 |
| NCT02191358 | Adverse Drug Events|Adverse Drug Reactions|Drug Interaction Potentiation|Drug Metabolism, Poor, CYP2D6-RELATED|Drug Metabolism, Poor, CYP2C19-RELATED|Cytochrome P450 Enzyme Deficiency|Cytochrome P450 CYP2D6 Enzyme Deficiency|Cytochrome P450 CYP2C9 Enzyme Deficiency|Cytochrome P450 CYP2C19 Enzyme Deficiency|Cytochrome P450 CYP3A Enzyme Deficiency|Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant|Poor Metabolizer Due to Cytochrome P450 CYP2C19 Variant|Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant | Genelex Corporation|University of Utah | | 2014-10-01 | 2017-02-27 |
